insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>177</sup>Lu]Lu-DOTA-Ahx-Lys40-Exendin-4 ([<sup>177</sup>Lu]Lu-DOTA-Exendin-4) is a potential agent for radiotherapy of insulinomas owing to its specificity towards GLP-1 (Glucagon like peptide-1) receptors over-expressed on such cancers.
|
31731177 |
2020 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to assess the diagnostic accuracy of a Tc-99m-labelled GLP-1R agonist [Lys<sup>40</sup>(AhxHYNIC-[<sup>99m</sup>Tc]EDDA)NH<sub>2</sub>]-exendin-4 for localization of occult insulinoma.
|
31098984 |
2020 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
[<sup>68</sup>Ga]Ga-NOTA-MAL-Cys<sup>39</sup>-exendin-4 was easily synthesized with high yield, favorable biodistribution and high affinity to islet tumor cell, making the tracer may have great potential in the detection of GLP-1R positive tumor such as an insulinoma.
|
31450071 |
2020 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study showed that <sup>18</sup>F-FDOPA PET/CT combined with carbidopa premedication and early pancreatic acquisitions is a valuable diagnostic option in patients with insulinoma when GLP1R-based imaging is not available.
|
30617961 |
2019 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The BV-mediated exogenous hGLP-1R in target cells showed same ligand-receptor binding characteristics compared with its counterpart in insulinoma cells.
|
30560451 |
2019 |
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As highly expressed in insulinomas, the glucagon-like peptide-1 receptor (GLP-1R) is believed to be an attractive target for diagnosis, localization, and treatment with radiolabeled exendin 4.
|
31181890 |
2019 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide 1 receptor analogs have recently shown promising results in preoperative localization of these tumors, as all insulinomas express glucagon-like peptide 1 receptors.
|
31107750 |
2019 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiolabeled exendin-4, a ligand of GLP-1R, has routinely been used in clinics to image insulinomas.
|
31393738 |
2019 |
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Being highly expressed in insulinomas, the glucagonlike peptide-1 receptor (GLP-1R) is a potential target for diagnosis, localization, and treatment with the radiolabeled GLP-1R agonist exendin.
|
30504139 |
2019 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The purpose of the study was to test the diagnostic accuracy and clinical impact of glucagon-like peptide-1 receptor (GLP-1R) PET/CT using <sup>68</sup>Ga-DOTA-exendin-4 in consecutive adult patients referred for localisation of insulinomas.
|
30054698 |
2018 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 receptors are ideal targets for preoperative imaging of benign insulinoma and for quantifying the beta cell mass.
|
28103285 |
2017 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiolabeled GLP-1 and its analog Exendin-4, have been employed in diabetes and insulinoma.
|
28365524 |
2017 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells.
|
28947919 |
2017 |
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Benign insulinoma has near ubiquitous dense GLP-1R expression enabling accurate localisation with radiolabelled-exendin-4 compounds (e.g.
|
28400403 |
2017 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we synthesized a novel indium-111 (<sup>111</sup>In)-benzyl-diethylenetriaminepentaacetic acid (<sup>111</sup>In-BnDTPA)-conjugated exendin(9-39), <sup>111</sup>In-BnDTPA-exendin(9-39), and evaluated its utility as a probe for the SPECT imaging of insulinoma. natIn-BnDTPA-exendin(9-39) exhibited a high affinity for GLP-1R (IC<sub>50</sub>=2.5nM), stability in plasma, and a specific activity that improved following reactions with a solvent and solubilizer.
|
28089587 |
2017 |
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Benign insulinomas express the glucagon-like peptide-1 receptor (GLP-1R, which recognizes exendin-4 and low levels of the somatostatin receptor (SSTR, which recognizes octreotide), whereas malignant insulinomas overexpress SSTR and low levels of GLP-1R.
|
28953210 |
2017 |
insulinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GLP1R was expressed in all eight insulinomas (100 %) but so in only four out of 14 cases (29 %) of non-insulinomas.
|
25119061 |
2014 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GLP-1 stimulated ABA release from an insulinoma cell line and from human islets, by ∼10- and 2-fold in low and high glucose, respectively.
|
22075645 |
2012 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, most of the somatostatin receptor-negative NET and GLP-1 receptor-negative malignant insulinomas are GIP receptor positive.
|
22112810 |
2012 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiolabelled glucagon-like peptide 1 (GLP-1) receptor agonists have recently been shown to successfully image benign insulinomas in patients.
|
21210113 |
2011 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting GLP-1R by (111)In-DOTA-exendin-4 or (111)In-DPTA-exendin-4 offers a new approach that permits the successful localization of small benign insulinomas.
|
21095545 |
2010 |
insulinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates the molecular cloning of a cDNA for the GLP-1 receptor from a human insulinoma employing a lambda-gt11 cDNA library.
|
7517895 |
1994 |